1. Home
  2. HRMY vs NYAX Comparison

HRMY vs NYAX Comparison

Compare HRMY & NYAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • NYAX
  • Stock Information
  • Founded
  • HRMY 2017
  • NYAX 2005
  • Country
  • HRMY United States
  • NYAX Israel
  • Employees
  • HRMY N/A
  • NYAX N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • NYAX
  • Sector
  • HRMY Health Care
  • NYAX
  • Exchange
  • HRMY Nasdaq
  • NYAX Nasdaq
  • Market Cap
  • HRMY 1.8B
  • NYAX 1.7B
  • IPO Year
  • HRMY 2020
  • NYAX N/A
  • Fundamental
  • Price
  • HRMY $34.00
  • NYAX $43.59
  • Analyst Decision
  • HRMY Strong Buy
  • NYAX Buy
  • Analyst Count
  • HRMY 9
  • NYAX 6
  • Target Price
  • HRMY $54.44
  • NYAX $41.67
  • AVG Volume (30 Days)
  • HRMY 642.5K
  • NYAX 21.1K
  • Earning Date
  • HRMY 08-05-2025
  • NYAX 08-06-2025
  • Dividend Yield
  • HRMY N/A
  • NYAX N/A
  • EPS Growth
  • HRMY 13.13
  • NYAX N/A
  • EPS
  • HRMY 2.62
  • NYAX 0.18
  • Revenue
  • HRMY $744,852,000.00
  • NYAX $331,161,000.00
  • Revenue This Year
  • HRMY $20.10
  • NYAX $33.44
  • Revenue Next Year
  • HRMY $18.01
  • NYAX $23.74
  • P/E Ratio
  • HRMY $13.10
  • NYAX $245.78
  • Revenue Growth
  • HRMY 20.62
  • NYAX 34.05
  • 52 Week Low
  • HRMY $26.47
  • NYAX $20.31
  • 52 Week High
  • HRMY $41.61
  • NYAX $52.46
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 58.91
  • NYAX 41.33
  • Support Level
  • HRMY $31.70
  • NYAX $42.88
  • Resistance Level
  • HRMY $35.08
  • NYAX $52.46
  • Average True Range (ATR)
  • HRMY 0.95
  • NYAX 1.30
  • MACD
  • HRMY 0.27
  • NYAX -0.89
  • Stochastic Oscillator
  • HRMY 71.80
  • NYAX 7.46

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About NYAX Nayax Ltd.

Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It provides consumers with digital, cashless payments, and connected commerce experiences, enhancing consumer conversion and loyalty. Its platform addresses the entire unattended commerce value chain, including a payments infrastructure, a commerce software suite, a consumer engagement platform, and integrated POS devices. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.

Share on Social Networks: